

## Supporting Information

Metal-free synthesis of  $\gamma$ -ketosulfones through Brønsted acid-promoted conjugate addition of sulfinamides

Nicolas Gigant,<sup>\*a</sup> Sami Kayal,<sup>a</sup> Emmanuelle Drège<sup>a</sup> and Delphine Joseph<sup>\*a</sup>

Université Paris-Saclay, CNRS, BioCIS, 91400 Orsay, France

*delphine.joseph@universite-paris-saclay.fr*

### Table of contents

1. General information .....	2
2. Experimental procedures .....	2
2.1. Preparation of Starting Materials.....	2
2.2. Preparation of ketosulfones <b>3</b> or alkoxy sulfones <b>4</b> .....	5
3. Copies of <sup>1</sup> H and <sup>13</sup> C spectra.....	15

## 1. General information


Reagents were purchased as reagent grade and were used without further purification other than those above-mentioned.  $\text{CH}_2\text{Cl}_2$  was purified by passage through a drying column and THF was distilled from sodium/benzophenone immediately prior to use.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR were recorded on a Bruker AC300 spectrometer at 300 MHz in  $\text{CDCl}_3$  at 25°C. Chemical shifts values are given in ppm downfield from tetramethylsilane (TMS) with the chloroform resonance as the internal standard. The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, q = quartet, qt = quintuplet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, br = broad. Coupling constants ( $J$ ) are reported in Hz and refer to apparent peak multiplications. Infrared (IR) spectra were recorded as neat films on Bruker Vector22 spectrophotometer. Mass spectra and high resolution mass spectra were obtained on a Thermoquest TLM LCQ Deca ion-trap spectrometer with a Q-TOF micro spectrometer using ESI. Melting points are uncorrected and were recorded on a micromelting point apparatus. Analytical thin layer chromatography was performed on Merck 60F-254 precoated silica (0.2 mm) on glass and was revealed by UV light or by spraying with a potassium permanganate solution, followed by charring at 150 °C. Flash chromatography separations were carried out on on Merck Kieselgel (40-63 $\mu\text{m}$ ).

Vinylketones **1h**, **1i** and **1j**,<sup>1</sup> **1k**,<sup>2</sup> **1m**<sup>3</sup> and sulfonamide **1b**<sup>4</sup> were synthesised according to the literature procedures.

## 2. Experimental procedures

### 2.1. Preparation of Starting Materials

#### 1-(Thien-2-yl)but-3-en-2-one (**1e**)



To a solution of *N*-methoxy-*N*-methyl-2-(thien-2-yl)acetamide<sup>5</sup> (300 mg, 1.62 mmol) in dry THF (30 mL) was added dropwise vinylmagnesium bromide solution 1.0 M in THF (3.24 mL, 3.24 mmol) at 0 °C. The mixture was then stirred 12 hours at room temperature before quenching by an aqueous saturated solution of  $\text{NH}_4\text{Cl}$  (10 mL). The aqueous layer was then extracted with  $\text{AcOEt}$  (2  $\times$  20 mL) and the combined organic extracts were washed with brine, dried over  $\text{MgSO}_4$ , filtered and concentrated. Flash chromatography (cyclohexane/ethyl acetate: 9/1) afforded the compound **1e** as a yellow oil (113 mg, 46 %).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  3107, 1694, 1674, 1533, 920;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.22 (dd,  $J$  = 5.2 Hz, 1.1 Hz, 1H), 6.98 (br t,  $J$  = 3.5 Hz, 1H), 6.90 (m, 1H), 6.45 (dd,  $J$  = 17.5, 10.1 Hz, 1H), 6.33 (dd,  $J$  = 17.5, 1.4 Hz, 1H), 5.86 (dd,  $J$  = 10.0 Hz, 1.4 Hz, 1H), 4.06 (s, 2H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  196.1, 135.1, 134.3, 129.5, 127.2, 127.0, 125.3, 41.0; HRMS (TOF-ESI)  $m/z$ : no satisfying analysis was obtained due to the low stability of the product.

<sup>1</sup> J. Barluenga, H. Fanlo, S. López and J. Flórez, *Angew. Chem. Int. Ed.*, 2007, **46**, 4136-4140.


<sup>2</sup> M. Radi, M. Pagano, L. Franchi, D. Castagnolo, S. Schenone, G. Casaluze, C. Zamperini, E. Dreassi, G. Maga, A. Samuele, E. Gonzalo, B. Clotet, J. A. Esté and M. Botta, *ChemMedChem*, 2012, **7**, 883-896.

<sup>3</sup> H. Pessoa-Mahana, G. Recabarren-Gajardo, J. Fiedler Temer, G. Zapata-Torres, C. D. Pessoa-Mahana, C. Saitz Barría and R. Araya-Maturana, *Molecules*, 2012, **17**, 1388-1407.

<sup>4</sup> J. L. García Ruano, A. Parra, F. Yuste and V. M. Mastranzo, *Synthesis*, 2008, 311-312.

<sup>5</sup> T. Kambe, T. Maruyama, M. Nakano, Y. Yamaura, T. Shono, A. Seki, K. Sakata, T. Maruyama, H. Nakai and M. Toda, *Chem. Pharm. Bull.*, 2011, **59**, 1523-1534.


### 1-(1-Tosyl-1*H*-indol-3-yl)vinylketone (**1n**)




A solution of 1-(1-tosyl-1*H*-indol-3-yl)prop-2-en-1-ol<sup>6</sup> (150 mg, 0.46 mmol) and MnO<sub>2</sub> (240 mg, 2.75 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was stirred at room temperature for 4 hours. Three new portions of MnO<sub>2</sub> (3x240 mg, 3x2.75 mmol) were successively added each 12 hours to the reaction mixture. The solution was then filtered through Celite<sup>®</sup> and washed with CH<sub>2</sub>Cl<sub>2</sub>. After evaporation of the solvent, flash chromatography (cyclohexane/ethyl acetate: 75/25 to 7/3) afforded the compound **1n** as a brown foam (92 mg, 61 %).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  3104, 1651, 1604, 1535, 1379, 1175, 993; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.38 (dd,  $J = 6.7, 2.6$  Hz, 1H), 8.25 (s, 1H), 7.93 (dd,  $J = 6.5$  Hz, 2.1 Hz, 1H), 7.82 (d,  $J = 8.3$  Hz, 2H), 7.39-7.34 (m, 2H), 7.27 (d,  $J = 8.2$  Hz, 2H), 7.04 (dd,  $J = 16.7, 10.4$  Hz, 1H), 6.47 (dd,  $J = 16.9, 1.1$  Hz, 1H), 5.88 (dd,  $J = 10.1, 1.1$  Hz, 1H), 2.37 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  185.6, 146.1, 135.1, 134.6, 133.2, 132.2, 130.4 (2C), 128.7, 128.0, 127.3, 126.1, 125.0, 123.4, 121.5, 113.2, 21.7; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>18</sub>H<sub>16</sub>NO<sub>3</sub>S [M + H]<sup>+</sup> 326.0845, found 326.0855.

The 1-[[**(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohex-1-yl**]oxy]but-3-en-2-one **1o** was synthesized by a sequence of procedures shown below:



### 2-[[**(1*R*,2*S*,5*R*)-2-isoPropyl-5-methylcyclohex-1-yl**]oxy]-*N*-methoxy-*N*-methylacetamide (**8**)<sup>7</sup>




To a solution of (-)-menthoxy acetic acid (320 mg, 1.50 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added *N,O*-dimethyl hydroxylamine hydrochloride (156 mg, 1.59 mmol), CBr<sub>4</sub> (540 mg, 1.59 mmol) and pyridine (128  $\mu$ L, 1.59 mmol). PPh<sub>3</sub> (420 mg, 1.59 mmol) was then added portion-wise, and the solution was stirred at room temperature for 14 hours. After evaporation of the solvent, flash chromatography (cyclohexane/ethyl acetate: 7/3) afforded compound **8** as a colourless oil (280 mg, 73 %).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2954, 2920, 2869, 1693, 1453, 1136, 1086, 996; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.30 (d,  $J = 15.2$  Hz, 1H), 4.20 (d,  $J = 15.2$  Hz, 1H), 3.68 (s, 3H), 3.18 (s, 3H), 2.30 (m, 1H), 2.10 (br d,  $J = 11.4$  Hz, 1H), 1.61 (m, 2H), 1.34-1.26 (m, 2H), 1.03-0.93 (m, 2H), 0.90 (d,  $J = 6.9$  Hz, 3H), 0.88 (d,  $J = 6.9$  Hz, 3H), 0.78 (d,  $J = 6.9$  Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  151.0, 80.1, 66.1, 61.5, 48.4, 40.2, 34.6, 31.7, 25.5, 23.4, 22.4, 21.1 (2C), 16.3; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>14</sub>H<sub>27</sub>NO<sub>3</sub>Na [M + Na]<sup>+</sup> 280.1883, found 280.1880.

<sup>6</sup> S. Breitler and E. M. Carreira, *J. Am. Chem. Soc.*, 2015, **137**, 5296-5299.



<sup>7</sup> The title product was synthesized according to the following procedure: H.A. Duong, R. E. Gilligan, M. L. Cooke, R. J. Phipps and M. J. Gaunt, *Angew. Chem. Int. Ed.*, 2011, **50**, 463-466.

**1-[[1*R*,2*S*,5*R*]-2-isoPropyl-5-methylcyclohex-1-yl]oxy]but-3-en-2-one (1o)**

To a solution of the previous menthol-derived Weinreb amide **8** (100 mg, 0.39 mmol) in dry THF (10 mL) was added dropwise vinylmagnesium bromide solution 1.0 M in THF (780  $\mu$ L, 0.78 mmol) at 0 °C. The mixture was then stirred 2 hours at room temperature before quenching by an aqueous saturated solution of  $\text{NH}_4\text{Cl}$  (4 mL). The aqueous layer was then extracted with AcOEt (10 mL) and the combined organic extracts were washed with brine, dried over  $\text{MgSO}_4$ , filtered and concentrated. Flash chromatography (cyclohexane/ethyl acetate: 95/5) afforded the compound **1o** as a colourless oil (61 mg, 70 %).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2955, 2920, 2870, 1702, 1453, 1411, 1111;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.60 (dd,  $J = 17.6, 10.6$  Hz, 1H), 6.32 (dd,  $J = 17.6, 1.4$  Hz, 1H), 5.78 (dd,  $J = 10.6, 1.4$  Hz, 1H), 4.30 (d,  $J = 16.5$  Hz, 1H), 4.14 (d,  $J = 16.5$  Hz, 1H), 3.12 (td,  $J = 10.5, 4.1$  Hz, 1H), 2.24 (qtd,  $J = 7.0, 2.6$  Hz, 1H), 2.04 (br d,  $J = 11.9$  Hz, 1H), 1.64-1.60 (m, 2H), 1.34-1.26 (m, 2H), 0.94-0.81 (m, 2H), 0.92 (d,  $J = 6.9$  Hz, 3H), 0.88 (d,  $J = 6.9$  Hz, 3H), 0.76 (d,  $J = 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  198.0, 132.7, 129.0, 80.4, 73.1, 48.3, 40.1, 34.1, 31.7, 25.7, 23.4, 22.4, 21.1, 16.3; HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{14}\text{H}_{24}\text{O}_2\text{Na}$  [ $\text{M} + \text{Na}$ ] $^+$  247.1669, found 247.1674.


The **(11*Z*,14*Z*)-icosa-1,11,14-trien-3-one** was synthesized by a sequence of procedures shown below:

**(9*Z*,12*Z*)-*N*-Methoxy-*N*-methyloctadeca-9,12-dienamide (9)**

To a solution of linoleic acid (460  $\mu$ L, 1.50 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (1 mL) was added *N,O*-dimethyl hydroxylamine (215 mg, 2.25 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethyl carbodiimide hydrochloride (430 mg, 2.25 mmol) and DMAP (275 mg, 2.25 mmol). The mixture was stirred at room temperature for 48 hours before quenching by addition of a saturated solution of  $\text{NH}_4\text{Cl}$  (1 mL). The aqueous layer was then extracted with  $\text{CH}_2\text{Cl}_2$  (2 $\times$ 10 mL) and the combined organic extracts were washed with brine, dried over  $\text{MgSO}_4$ , filtered and concentrated. Flash chromatography (cyclohexane/ethyl acetate: 9/1) afforded compound **9** as a colourless oil (259 mg, 53 %).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2926, 2854, 1670, 1464, 1382, 1177, 989, 722;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  5.41-5.27 (m, 4H, =CH), 3.67 (s, 3H), 3.17 (s, 3H), 2.76 (t,  $J = 5.8$  Hz, 2H), 2.40 (t,  $J = 7.4$  Hz, 2H), 2.03 (m, 4H), 1.62 (m, 2H), 1.30 (m, 14H), 0.88 (t,  $J = 7.1$  Hz, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  153.4, 130.3, 130.2, 128.1, 128.1, 61.3, 32.4, 32.1, 31.7, 29.8, 29.6, 29.5 (2C), 29.3, 27.3 (2C), 25.8, 24.8, 22.7, 14.2; HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{20}\text{H}_{37}\text{O}_2\text{N}_2$  [ $\text{M} + \text{Na}$ ] $^+$  346.2717, found 346.2731.


### (11Z,14Z)-Icosa-1,11,14-trien-3-one (1p)



To a solution of the previous linoleic Weinreb amide **9** (230 mg, 0.71 mmol) in dry THF (4.5 mL) was added dropwise vinylmagnesium bromide solution 1.0 M in THF (1.78 mL, 1.78 mmol) at 0 °C. The mixture was then stirred 4 hours at room temperature before quenching by a saturated solution of NH<sub>4</sub>Cl (2 mL). The aqueous layer was then extracted with AcOEt (2×10 mL) and the combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated. Flash chromatography (cyclohexane/ethyl acetate: 95/5) afforded the compound **1p** as a colourless oil (173 mg, 84 %).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2926, 2854, 1684, 1466, 1399, 954, 724; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  6.35 (dd,  $J$  = 17.7, 10.3 Hz, 1H), 6.20 (dd,  $J$  = 17.7, 1.2 Hz, 1H), 5.80 (dd,  $J$  = 10.3, 1.2 Hz, 1H), 5.40-5.28 (m, 4H), 2.77 (t,  $J$  = 5.7 Hz, 2H), 2.57 (t,  $J$  = 7.4 Hz, 2H), 2.03 (m, 4H), 1.61 (m, 2H), 1.30 (m, 14H), 0.88 (t,  $J$  = 6.9 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  201.2, 136.7, 130.3, 130.2, 128.2, 128.0, 127.9, 39.8, 31.7, 29.7, 29.5 (2C), 29.4, 29.3, 27.3 (2C), 25.8, 24.1, 22.7, 14.2; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>20</sub>H<sub>34</sub>O<sub>Na</sub> [M + Na]<sup>+</sup> 313.2502, found 313.2502.

### N-Octyl-tert-butylsulfonamide (2d)



A solution of *tert*-butylsulfonamide (300 mg, 2.48 mmol), octanal (778  $\mu$ L, 4.96 mmol) and anhydrous CuSO<sub>4</sub> (790 mg, 4.96 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was stirred at room temperature overnight. The resulting mixture was then filtrated through Celite®, washed with CH<sub>2</sub>Cl<sub>2</sub> and evaporated. The residue was dissolved in MeOH (10 mL) and cooled to 0 °C before adding NaBH<sub>4</sub> (470 mg, 14.4 mmol). The mixture was then stirred 4 hours more before quenching by addition of acetone (2 mL). After evaporation of the solvent and addition of water (2 mL), the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×10 mL). The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was then purified by flash chromatography (cyclohexane/ethyl acetate: 4/6 to 3/7) to yield the desired product **2d** as a colourless oil (512 mg, 88%).


IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2924, 2854, 1469, 1055; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.62 (t,  $J$  = 6.5 Hz, 1H), 3.22-3.01 (m, 2H), 1.54 (m, 2H), 1.40-1.21 (m, 10H), 1.20 (s, 9H), 0.87 (t,  $J$  = 6.1 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  63.2, 55.6, 45.9, 33.0, 31.9, 31.2, 29.3, 26.9, 22.7 (3C), 14.2; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>12</sub>H<sub>27</sub>NONaS [M + Na]<sup>+</sup> 256.1706, found 256.1711.

## 2.2. Preparation of ketosulfones **3** or alkoxyulfones **4**

### General procedure for the synthesis of ketosulfones **3**

To a solution of alkene **1** (0.20 mmol) in CH<sub>3</sub>CN ( $c$  = 0.4 mol.L<sup>-1</sup>) were successively added sulfonamide **2** (0.40 mmol) and aqueous HBF<sub>4</sub> 48% wt. (0.20 mmol). The resulting mixture was stirred at room temperature until disappearance of the starting material (4 to 48 hours) before quenching by addition of water (2 mL). The solution was then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×10 mL). The organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated. Crude product was purified by flash chromatography with cyclohexane/ethyl acetate to yield the desired ketosulfone **3**.


### 3-(*tert*-Butylsulfonyl)cyclohexanone (**3aa**)



**3aa** was prepared following the general procedure by reacting **1a** (19.4  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 24 hours. Flash chromatography (cyclohexane/ethyl acetate: 4/6) afforded the title compound **3aa** as a white solid (32 mg, 73%).

M.p.: 108-109 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2968, 1705, 1270, 1110, 664; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.57-3.47 (m, 1H), 2.75 (d, *J* = 9.1 Hz, 2H), 2.40-2.21 (m, 4H), 2.08-1.97 (m, 1H), 1.75-1.63 (m, 1H), 1.42 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  207.4, 61.4, 55.8, 42.4, 40.5, 25.3, 24.2 (3C), 23.8; HRMS (TOF-ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>18</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 241.0869, found 241.0875.


### 3-(Benzenesulfonyl)cyclohexanone (**3ab**)



**3ab** was prepared following the general procedure by reacting **1a** (19.4  $\mu$ L, 0.20 mmol), benzenesulfonamide **2b** (56 mg, 0.40 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 24 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3 to 6/4) afforded the title compound **3ab** as a white solid (44 mg, 92%).

M.p.: 87-88 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2965, 1706, 1260, 1137, 1084, 1019, 798; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.85 (br d, *J* = 7.2 Hz, 2H), 7.68 (br t, *J* = 7.7 Hz, 1H), 7.57 (br t, *J* = 7.2 Hz, 2H), 3.33-3.23 (m, 1H), 2.57 (m, 2H), 2.41-2.17 (m, 4H), 1.91 (qd, *J* = 12.7, 3.1 Hz, 1H), 1.71-1.57 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  206.6, 136.8, 134.4, 129.6 (2C), 129.1 (2C), 62.4, 40.6, 40.5, 23.8, 23.6; HRMS (TOF-ESI) *m/z*: Calcd for C<sub>12</sub>H<sub>14</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 261.0556, found 261.0562. The data presented above is in agreement with that detailed in the literature.<sup>8</sup>

### 3-Tosylcyclohexanone (**3ac**)




**3ac** was prepared following the general procedure by reacting **1a** (19.4  $\mu$ L, 0.20 mmol), *p*-toluenesulfonamide **2c** (62 mg, 0.40 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 24 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3 to 6/4) afforded the title compound **3ac** as a yellow solid (38 mg, 75%).

M.p.: 82-83 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2952, 1713, 1283, 1086, 1018, 664; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.72 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 8.1 Hz, 2H), 3.30-3.20 (m, 1H), 2.53 (m, 2H), 2.44 (s, 3H), 2.41-2.18 (m, 4H), 1.95-1.73 (m, 1H), 1.67-1.58 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  206.7, 145.4, 133.6, 130.1 (2C), 129.0 (2C), 62.4, 40.6 (2C), 23.8, 23.6, 21.7; HRMS (TOF-ESI) *m/z*:

<sup>8</sup> N. K. Jana and J. G. Verkade, *Org. Lett.*, 2003, **5**, 3787-3790.

Calcd for  $C_{13}H_{16}O_3NaS$   $[M + Na]^+$  275.0712, found 275.0721. The data presented above are in agreement with that detailed in the literature.<sup>9</sup>


#### 4-(*tert*-Butylsulfonyl)butan-2-one (**3ca**)



**3ca** was prepared following the general procedure by reacting **1c** (16.7  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $HBF_4$  (26  $\mu$ L, 0.20 mmol) for 7 hours. Flash chromatography (cyclohexane/ethyl acetate: 3/7) afforded the title compound **3ca** as a white solid (26 mg, 68%).

M.p.: 56-57 °C; IR (neat)  $\nu_{max}/cm^{-1}$  2978, 1714, 1475, 1300, 1160, 1108 (CH);  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  3.20 (t,  $J$  = 6.9 Hz, 2H), 3.02 (t,  $J$  = 7.7 Hz, 2H), 2.24 (s, 3H), 1.41 (s, 9H);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ )  $\delta$  204.7, 59.2, 40.2, 34.1, 30.1, 23.4 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for  $C_8H_{16}O_3NaS$   $[M + Na]^+$  215.0712, found 215.0719. The data presented above are in agreement with that detailed in the literature.<sup>10</sup>


#### 1-(*tert*-Butylsulfonyl)pentan-3-one (**3da**)



**3da** was prepared following the general procedure by reacting **1d** (19.9  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $HBF_4$  (26  $\mu$ L, 0.20 mmol) for 7 hours. Flash chromatography (cyclohexane/ethyl acetate: 5/5 to 4/6) afforded the title compound **3da** as a white solid (39 mg, 95%).

M.p.: 55-56 °C; IR (neat)  $\nu_{max}/cm^{-1}$  2978, 1714, 1414, 1265, 1114, 976;  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  3.21 (t,  $J$  = 6.9 Hz, 2H), 2.98 (t,  $J$  = 7.6 Hz, 2H), 2.51 (q,  $J$  = 7.3 Hz, 2H), 1.40 (s, 9H), 1.07 (t,  $J$  = 7.3 Hz, 3H);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ )  $\delta$  207.6, 59.1, 40.1, 36.2, 32.7, 23.4 (3C), 7.9; HRMS (TOF-ESI)  $m/z$ : Calcd for  $C_9H_{18}O_3NaS$   $[M + Na]^+$  229.0869, found 229.0865.

#### 4-(*tert*-Butylsulfonyl)-1-(thien-2-yl)butan-2-one (**3ea**)




**3ea** was prepared following the general procedure by reacting **1e** (30 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $HBF_4$  (26  $\mu$ L, 0.20 mmol) for 10 hours. Flash chromatography (cyclohexane/ethyl acetate: 75/25) afforded the title compound **3ea** as a white solid (35 mg, 64%).

M.p.: 84-85 °C; IR (neat)  $\nu_{max}/cm^{-1}$  2962, 1717, 1473, 1265, 1108, 1007, 669;  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  7.22 (dd,  $J$  = 5.1, 1.1 Hz, 1H), 6.98 (dd,  $J$  = 5.0, 3.6 Hz, 1H), 6.91 (m, 1H), 3.99 (s, 2H), 3.21 (t,  $J$  = 6.6 Hz, 2H), 3.08 (t,  $J$  = 6.8 Hz, 2H), 1.71 (s, 9H);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ )  $\delta$  203.5, 134.4, 127.5, 127.4, 125.7, 59.3, 43.9, 40.4, 32.5, 23.6 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for  $C_{12}H_{18}O_3NaS_2$   $[M + Na]^+$  297.0590, found 297.0592.

<sup>9</sup> N. K. Jana and J. G. Verkade, *Org. Lett.*, 2003, **5**, 3787-3790.

<sup>10</sup> M. J. Tilby, D. F. Dewez, L. R. E. Pantaine, A. Hall, C. Martínez-Lamenca and M. C. Willis, *ACS Catal.* 2022, **12**, 6060-6067.


### 1-Acetyl-2-*tert*-butylsulfonyl cyclohexane (3fa)



**3fa** was prepared following the general procedure by reacting **1f** (25.7  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 48 hours. Flash chromatography (cyclohexane/ethyl acetate: 5/5) afforded the title compound **3fa** as a brown foam (33 mg, 67%).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2944, 1711, 1271, 1110, 681; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  3.59 (m, 1H), 2.90 (m, 1H), 2.62-2.51 (m, 1H), 2.23 (s, 3H), 2.02 (m, 2H), 1.81-1.74 (m, 2H), 1.47-1.41 (m, 3H), 1.36 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  208.9, 61.1, 57.1, 48.3, 29.1, 27.6, 26.2, 24.6, 23.5 (3C), 21.9; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>12</sub>H<sub>22</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> 269.1182, found 269.1180.


### 3-(*tert*-Butylsulfonyl)propanal (3ga)



**3ga** was prepared following the general procedure by reacting **1g** (13.4  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (24 mg, 0.20 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 4 hours. Flash chromatography (cyclohexane/ethyl acetate: 3/7) afforded the title compound **3ga** as a colourless oil (14 mg, 39%).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2988, 1723, 1297, 1110; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.87 (s, 1H), 3.25 (t,  $J$  = 7.4 Hz, 2H), 3.10 (t,  $J$  = 7.0 Hz, 2H), 1.44 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  197.8, 59.4, 38.7, 34.8, 23.5 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>7</sub>H<sub>14</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 201.0556, found 201.0564.

### (*E*)-*N*-[3-(*tert*-Butylsulfonyl)propylidene-1-yl]-*tert*-butylsulfonamide (5ga)




**5ga** was prepared following the general procedure by reacting **1g** (13.4  $\mu$ L, 0.20 mmol), *tert*-butylsulfonamide **2a** (73 mg, 0.60 mmol), HBF<sub>4</sub> (26  $\mu$ L, 0.20 mmol) for 24 hours. Flash chromatography (cyclohexane/ethyl acetate: 3/7) afforded the title compound **5ga** as a white solid (14,5 mg, 26%).

M.p.: 101-102 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2985, 1651, 1300, 1263, 1117, 1078; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.19 (t,  $J$  = 3.1 Hz, 1H), 3.34-3.28 (m, 2H), 3.15-3.09 (m, 2H), 1.45 (s, 9H), 1.20 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  165.6, 59.4, 57.2, 41.2, 27.5, 23.6 (3C), 22.5 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>11</sub>H<sub>24</sub>NO<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 282.1192, found 282.1205.




### 3-(*tert*-Butylsulfonyl)-1-(4-chlorophenyl)propan-1-one (3ha)



**3ha** was prepared following the general procedure by reacting **1h** (33 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 5 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3) afforded the title compound **3ha** as a white solid (16 mg, 28%).

M.p.: 146-147 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2982, 1674, 1588, 1301, 1265, 1116; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.94 (d, *J* = 8.7 Hz, 2H), 7.45 (d, *J* = 8.7 Hz, 2H), 3.55 (dd, *J* = 8.5, 6.4 Hz, 2H), 3.38 (dd, *J* = 8.5, 6.5 Hz, 2H), 1.47 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  195.3, 140.5, 134.4, 129.7 (2C), 129.3 (2C), 59.3, 40.5, 29.8, 23.5 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>O<sub>3</sub>NaCl [M + Na]<sup>+</sup> 311.0479, found 311.0476.


### 3-(*tert*-Butylsulfonyl)-1-(4-fluorophenyl)propan-1-one (3ia)



**3ia** was prepared following the general procedure by reacting **1i** (30 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 5 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3 to 6/4) afforded the title compound **3ia** as a white solid (16 mg, 29%).

M.p.: 103-104 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2925, 1684, 1596, 1267, 1108, 979, 736; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.03 (m, 2H), 7.16 (br t, *J* = 8.7 Hz, 2H), 3.56 (dd, *J* = 8.4, 6.3 Hz, 1H), 3.38 (dd, *J* = 8.5, 6.4 Hz, 1H), 1.47 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  194.9, 166.3 (d, *J* = 254.4 Hz), 131.0 (d, *J* = 9.3 Hz, 2C), 116.1 (d, *J* = 21.9 Hz, 2C), 59.4, 40.7, 29.8, 23.6 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>O<sub>3</sub>NaF [M + Na]<sup>+</sup> 295.0775, found 295.0779.


### 3-(*tert*-Butylsulfonyl)-1-phenylpropan-1-one (3ja)



**3ja** was prepared following the general procedure by reacting **1h** (26.4 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 5 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3 to 6/4) afforded the title compound **3ja** as a white solid (31 mg, 61%).

M.p.: 120-121 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2935, 2920, 1687, 1262, 1108, 1002, 740, 688; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 (br d, *J* = 7.3 Hz, 2H), 7.60 (br t, *J* = 7.6 Hz, 1H), 7.49 (br t, *J* = 7.7 Hz, 2H), 3.60 (dd, *J* = 8.5, 6.6 Hz, 1H), 3.39 (dd, *J* = 8.6, 6.7 Hz, 1H), 1.47 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  196.5, 136.1, 133.9, 128.9, 128.3, 59.3, 40.6, 29.8, 23.6 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>18</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 277.0869, found 277.0887.


### 3-(*tert*-Butylsulfonyl)-1-(4-methoxyphenyl)propan-1-one (3ka)



**3ka** was prepared following the general procedure by reacting **1k** (32 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 4 hours. Flash chromatography (cyclohexane/ethyl acetate: 5/5) afforded the title compound **3ka** as a white solid (33 mg, 58%).

M.p.: 75-76 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2926, 1674, 1601, 1573, 1251, 1112, 977; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.97 (d, *J* = 8.9 Hz, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 3.87 (s, 3H), 3.54 (dd, *J* = 8.5, 6.8 Hz, 2H), 3.37 (dd, *J* = 8.5, 6.6 Hz, 1H), 1.46 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  194.9, 164.1, 130.6 (2C), 129.2, 114.1 (2C), 59.3, 55.7, 40.7, 29.3, 23.5 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>14</sub>H<sub>20</sub>O<sub>4</sub>NaS [M + Na]<sup>+</sup> 307.0975, found 307.0982.


### 3-(*tert*-Butylsulfonyl)-1,3-diphenylpropan-1-one (3la)



**3la** was prepared following the general procedure by reacting **1l** (42 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 48 hours. Flash chromatography (cyclohexane/ethyl acetate: 9/1 to 8/2) afforded the title compound **3la** as a white solid (38 mg, 57%).

M.p.: 136-137 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2926, 1687, 1281, 1177, 1108; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.92 (d, *J* = 7.3 Hz, 2H), 7.62 (d, *J* = 7.9 Hz, 2H), 7.55 (t, *J* = 7.1 Hz, 1H), 7.43 (m, 2H), 7.40-7.29 (m, 3H), 5.19 (dd, *J* = 9.2 Hz, *J* = 3.5 Hz, 1H), 4.15 (dd, *J* = 17.9 Hz, *J* = 3.5 Hz, 1H), 3.72 (dd, *J* = 17.9 Hz, *J* = 9.2 Hz, 1H), 1.24 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  195.4, 136.4, 135.0, 133.7, 129.9 (2C), 129.0 (3C), 128.8 (2C), 128.3 (2C), 62.4, 60.1, 39.6, 24.4 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>19</sub>H<sub>22</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 353.1182, found 353.1189.


### 3-(*tert*-Butylsulfonyl)-1-(thien-3-yl)propan-1-one (3ma)



**3ma** was prepared following the general procedure by reacting **1m** (28 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 6 hours. Flash chromatography (cyclohexane/ethyl acetate: 6/4) afforded the title compound **3ma** as a white solid (29 mg, 55%).

M.p.: 133-134 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  2952, 1669, 1416, 1264, 1106, 771; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.80 (d, *J* = 3.4 Hz, 1H), 7.67 (d, *J* = 4.9 Hz, 1H), 7.15 (t, *J* = 4.6 Hz, 1H), 3.52 (dd, *J* = 8.3, 6.2 Hz, 1H), 3.37 (dd, *J* = 8.5, 6.6 Hz, 1H), 1.45 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  189.1, 143.0, 134.6, 132.8, 128.5, 59.3, 40.5, 30.2, 23.5 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>16</sub>O<sub>3</sub>S<sub>2</sub>Na [M + Na]<sup>+</sup> 283.0433, found 283.0435.


### 3-(*tert*-Butylsulfonyl)-1-(1-tosyl-1*H*-indol-3-yl)propan-1-one (3na)



**3na** was prepared following the general procedure by reacting **1n** (65 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 24 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3 to 6/4) afforded the title compound **3na** as a brown solid (45 mg, 50%).

M.p.: 143-144 °C; IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2971, 1666, 1539, 1266, 1116, 978; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.34 (s, 1H), 8.25 (dd,  $J$  = 7.3, 2.2 Hz, 1H), 7.96 (dd,  $J$  = 6.9, 1.3 Hz, 1H), 7.85 (d,  $J$  = 8.4 Hz, 2H), 7.40-7.26 (m, 4H), 3.54-3.50 (m, 2H), 3.44-3.38 (m, 2H), 2.36 (s, 3H, CH<sub>3</sub>-Ar), 1.47 (s, 9H, *t*Bu); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  191.7, 146.2, 135.0, 134.5, 133.2, 132.5, 130.4 (2C), 127.4 (2C), 126.0, 125.1, 122.9, 120.4, 113.3, 59.4, 40.3, 30.7, 23.5 (3C), 21.8; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>22</sub>H<sub>25</sub>NO<sub>5</sub>NaS<sub>2</sub> [M + Na]<sup>+</sup> 470.1066, found 470.1073.


### 4-(*tert*-Butylsulfonyl)-1-[[1*R*,2*S*,5*R*]-2-isopropyl-5-methylcyclohex-1-yl]oxybut-3-en-2-one (3oa)



**3oa** was prepared following the general procedure by reacting **1o** (44 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) in a mixture of CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>CN (8/2, 1 mL) for 17 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3) afforded the title compound **3oa** as a yellow oil (41 mg, 59%).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2955, 2920, 1722, 1301, 1116; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.20 (d,  $J$  = 16.8 Hz, 1H), 4.00 (d,  $J$  = 16.8 Hz, 1H), 3.26-6.09 (m, 4H), 2.22 (m, 1H), 2.03 (br d,  $J$  = 11.3 Hz, 1H), 1.64 (m, 2H), 1.43 (s, 9H), 1.35-1.18 (m, 4H), 0.91 (m, 8H), 0.78 (d,  $J$  = 6.9 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  206.6, 80.6, 73.9, 59.3, 48.2, 40.0, 39.9, 34.5, 31.6, 30.5, 25.8, 23.5 (3C), 23.4, 22.4, 21.1, 16.4; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>18</sub>H<sub>34</sub>O<sub>4</sub>NaS [M + Na]<sup>+</sup> 369.2070, found 369.2080.

### (11*Z*,14*Z*)-1-(*tert*-Butylsulfonyl)icosa-11,14-dien-3-one (3pa)




**3pa** was prepared following the general procedure by reacting **1p** (58 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 6 hours. Flash chromatography (cyclohexane/ethyl acetate: 7/3) afforded the title compound **3pa** as a yellow foam (42 mg, 51%).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  2982, 1712, 1268, 1102; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.35-5.27 (m, 4H), 3.21 (t,  $J$  = 7.8 Hz, 2H), 2.99 (t,  $J$  = 7.2 Hz, 2H), 2.76 (t,  $J$  = 5.8 Hz, 2H), 2.49 (t,  $J$  = 7.4 Hz, 2H), 2.03 (m, 4H), 1.60 (m, 2H), 1.42 (s, 9H), 1.30 (m, 14H), 0.88 (t,  $J$  = 7.0 Hz, 3H, Me); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  207.3, 130.3, 130.2, 128.2, 128.0, 59.2, 43.1, 40.2, 33.1, 31.7, 29.7, 29.5, 29.4, 29.2, 28.2, 27.3, 25.8, 24.9, 23.9, 23.5 (3C), 22.7, 14.2; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>24</sub>H<sub>44</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 435.2903, found 435.2915.

### General procedure for the synthesis of hydroxysulfones **4**

The ketosulfone **3** (0.20 mmol) was dissolved in MeOH ( $c = 0.1 \text{ mol}\cdot\text{L}^{-1}$ ) at 0 °C and NaBH<sub>4</sub> (0.24 mmol) was then added. After stirring at room temperature for 2 hours, the reaction mixture was quenched by the addition of acetone (2 mL) before evaporation of the solvent. Water (2 mL) was then added, the aqueous layer was extracted with AcOEt (3×10 mL) and the combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product was purified by flash chromatography with cyclohexane/ethyl acetate to yield the desired hydroxysulfone **4**.


### 3-(*tert*-Butylsulfonyl)cyclopentanol (**4ba**)



**4ba** was prepared following the general procedure by reacting **1b** (32.8 μL, 0.40 mmol), *tert*-butylsulfonamide **2a** (96 mg, 0.80 mmol), HBF<sub>4</sub> (52 μL, 0.40 mmol) for 24 hours. NaBH<sub>4</sub> (18 mg, 0.48 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 1/9) afforded the title compound **4ba** as a white solid (73 mg, 88%, *cis/trans* = 10/1).

M.p.: 79-80 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  3499, 2993, 1282, 1143, 688; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.31 (br s, 1H), 3.72-3.62 (m, 1H), 2.47-2.20 (m, 4H), 2.13-2.06 (m, 1H), 2.02-1.91 (m, 1H), 1.79-1.72 (m, 1H), 1.44 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  72.4, 60.3, 55.7, 37.4, 35.6, 25.8, 24.3 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>9</sub>H<sub>18</sub>O<sub>3</sub>NaS [M+ Na]<sup>+</sup> 229.0869, found 229.0868.


### 3-(Benzenesulfonyl)cyclopentanol (**4bb**)



**4bb** was prepared following the general procedure by reacting **1b** (16.8 μL, 0.20 mmol), benzenesulfonamide **2b** (56 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 24 hours. NaBH<sub>4</sub> (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 3/7 to 2/8) afforded the title compound **4bb** as a colourless oil (30 mg, 66%, *cis/trans* = 21/1).

IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  3480, 1446, 1284, 1142, 1085; 690; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.91 (br d,  $J = 7.4 \text{ Hz}$ , 2H), 7.67 (br t,  $J = 7.8 \text{ Hz}$ , 1H), 7.57 (br t,  $J = 6.9 \text{ Hz}$ , 2H), 4.32 (br s, 1H), 3.61 (qt,  $J = 8.5 \text{ Hz}$ , 1H), 2.35-2.10 (m, 4H), 1.96-1.85 (m, 2H), 1.83-1.73 (m, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  138.2, 134.0, 129.5 (2C), 128.7 (2C), 72.7, 63.2, 36.3, 35.6, 24.8; HRMS (TOF-ESI)  $m/z$ : Calcd for C<sub>11</sub>H<sub>14</sub>O<sub>3</sub>NaS [M + Na]<sup>+</sup> 249.0556, found 249.0560.


### 3-(*p*-Toluensulfonyl)-cyclopentan-1-ol (**4bc**)



**4bc** was prepared following the general procedure by reacting **1b** (16.8 μL, 0.20 mmol), *p*-toluenesulfonamide **2c** (62 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 24 hours. NaBH<sub>4</sub> (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 4/6) afforded the title compound **4bc** as a colourless oil (58 mg, 75%, *cis/trans* = 17/1).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  3492, 1478, 1284, 1185;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.78 (d,  $J = 8.3$  Hz, 2H), 7.35 (d,  $J = 8.3$  Hz, 2H), 4.31 (br s, 1H), 3.58 (qt,  $J = 6.7$  Hz, 1H), 2.45 (s, 3H), 2.28-2.13 (m, 4H), 1.95-1.84 (m, 2H), 1.79-1.74 (m, 1H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  144.9, 135.0, 130.0 (2C), 128.6 (2C), 72.6, 63.2, 36.2, 35.5, 24.6, 21.6; HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{12}\text{H}_{16}\text{O}_3\text{NaS}$  [ $\text{M} + \text{Na}$ ] $^+$  263.0712, found 263.0710. The data presented above are in agreement with that detailed in the literature.<sup>11</sup>


### 3-(*tert*-Butylsulfonyl)-1-(4-chlorophenyl)propan-1-ol (**4ha**)



**4ha** was prepared following the general procedure by reacting **1h** (33 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $\text{HBF}_4$  (26  $\mu\text{L}$ , 0.20 mmol) for 5 hours.  $\text{NaBH}_4$  (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 4/6) afforded the title compound **4ha** as a colourless oil (11 mg, 18%).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  3469, 2924, 1282, 1110, 748;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.32 (m, 4H), 4.95 (dd,  $J = 8.5, 4.5$  Hz, 1H), 3.07 (t,  $J = 7.3$  Hz, 2H), 2.33-2.21 (m, 2H), 1.41 (s, 9H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  142.0, 133.8, 129.0 (2C), 127.2 (2C), 71.8, 59.3, 42.1, 30.2, 23.6 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{13}\text{H}_{19}\text{O}_3\text{NaS}$  [ $\text{M} + \text{Na}$ ] $^+$  313.0636, found 313.0638.


### 3-(*tert*-Butylsulfonyl)-1-(4-fluorophenyl)propan-1-ol (**4ia**)



**4ia** was prepared following the general procedure by reacting **1i** (30 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $\text{HBF}_4$  (26  $\mu\text{L}$ , 0.20 mmol) for 5 hours.  $\text{NaBH}_4$  (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 4/6 to 3/7) afforded the title compound **4ia** as a white solid (17 mg, 31%).

M.p.: 61-62  $^\circ\text{C}$ ; IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  3479, 2990, 1509, 1260, 1109;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34 (dd,  $J = 8.7$  Hz,  $J = 5.4$  Hz, 2H), 7.04 (t,  $J = 8.6$  Hz, 2H), 4.91 (dd,  $J = 8.0, 4.6$  Hz, 1H), 3.07 (t,  $J = 7.5$  Hz, 2H), 2.52 (br s, 1H), 2.31-2.22 (m, 2H), 1.41 (s, 9H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  162.5 (d,  $J = 245$  Hz), 139.3, 127.5 (d,  $J = 8.0$  Hz, 2C), 115.6 (d,  $J = 21.3$  Hz, 2C), 71.9, 59.3, 42.2, 30.2, 23.6 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{13}\text{H}_{19}\text{O}_3\text{FNaS}$  [ $\text{M} + \text{Na}$ ] $^+$  297.0931, found 297.0937.

### 3-(*tert*-Butylsulfonyl)-1-(4-methoxyphenyl)propan-1-ol (**4ka**)




**4ka** was prepared following the general procedure by reacting **1k** (32 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol),  $\text{HBF}_4$  (26  $\mu\text{L}$ , 0.20 mmol) for 4 hours.  $\text{NaBH}_4$  (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 4/6) afforded the title compound **4ka** as a yellow oil (28 mg, 49%).

IR (neat)  $\nu_{\max}/\text{cm}^{-1}$  3490, 2938, 1672, 1512, 1244, 1109, 1030;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.27 (d,  $J = 8.7$  Hz, 2H), 6.88 (d,  $J = 8.6$  Hz, 2H), 4.84 (t,  $J = 6.5$  Hz, 2H), 3.80 (s, 3H), 3.11-2.98 (m, 2H), 2.27 (q,  $J = 7.5$  Hz, 2H), 1.40 (s, 9H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  159.5, 135.6, 127.1 (2C), 114.2 (2C), 72.3, 59.2, 55.4, 42.5, 30.0, 23.6 (3C); HRMS (TOF-ESI)  $m/z$ : Calcd for  $\text{C}_{14}\text{H}_{22}\text{O}_4\text{NaS}$  [ $\text{M} + \text{Na}$ ] $^+$  309.1131, found 309.1143.

<sup>11</sup> M. Fernández, U. Uria, L. Orbe, J. L. Vicario, E. Reyes and L. Carrillo, *J. Org. Chem.*, 2014, **79**, 441-445.

**3-(*tert*-Butylsulfonyl)-1-(thien-3-yl)propan-1-ol (4ma)**




**4ma** was prepared following the general procedure by reacting **1m** (28 mg, 0.20 mmol), *tert*-butylsulfonamide **2a** (48 mg, 0.40 mmol), HBF<sub>4</sub> (26 μL, 0.20 mmol) for 6 hours. NaBH<sub>4</sub> (9.1 mg, 0.24 mmol) was next added. Flash chromatography (cyclohexane/ethyl acetate: 4/6) afforded the title compound **4ma** as a white solid (24 mg, 47%).


M.p.: 82-83 °C; IR (neat)  $\nu_{\text{max}}/\text{cm}^{-1}$  3473, 297, 1255, 1086, 777; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.25 (d, *J* = 4.7 Hz, 1H), 7.00-6.96 (m, 2H), 5.17 (dd, *J* = 7.3, 5.3 Hz, 1H), 3.11 (t, *J* = 7.4 Hz, 2H), 2.71 (br s, 1H), 2.45-2.35 (m, 2H), 1.41 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  147.2, 127.0, 125.0, 124.1, 68.6, 59.3, 42.2, 30.3, 25.6 (3C); HRMS (TOF-ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>18</sub>O<sub>2</sub>NaS<sub>2</sub> [M + Na]<sup>+</sup> 285.0590, found 285.0601.

### 3. Copies of $^1\text{H}$ and $^{13}\text{C}$ spectra


7.235  
7.231  
7.218  
7.214  
6.990  
6.978  
6.961  
6.907  
6.904  
6.896  
6.893  
6.500  
6.467  
6.442  
6.408  
6.363  
6.359  
6.305  
6.300  
5.884  
5.879  
5.851  
5.846




**1e**, CDCl<sub>3</sub>, 300 MHz










**1e**, CDCl<sub>3</sub>, 75 MHz







**1n**, CDCl<sub>3</sub>, 300 MHz







**1n**, CDCl<sub>3</sub>, 75 MHz







**8**, CDCl<sub>3</sub>, 300 MHz







**8**, CDCl<sub>3</sub>, 75 MHz







**1o**, CDCl<sub>3</sub>, 300 MHz






**1o**, CDCl<sub>3</sub>, 75 MHz







**9**, CDCl<sub>3</sub>, 300 MHz










**9**, CDCl<sub>3</sub>, 75 MHz







**1p**, CDCl<sub>3</sub>, 300 MHz







**1p**, CDCl<sub>3</sub>, 75 MHz







**2d**, CDCl<sub>3</sub>, 300 MHz







**2d**, CDCl<sub>3</sub>, 75 MHz







**3aa**, CDCl<sub>3</sub>, 300 MHz






**3aa**, CDCl<sub>3</sub>, 75 MHz







**3ab**, CDCl<sub>3</sub>, 300 MHz










**3ab**, CDCl<sub>3</sub>, 75 MHz







**3ac**, CDCl<sub>3</sub>, 300 MHz






**3ac**, CDCl<sub>3</sub>, 75 MHz






**3ca**, CDCl<sub>3</sub>, 300 MHz



—204.72



**3ca**, CDCl<sub>3</sub>, 75 MHz


—59.18


—40.16

—34.06


—30.12

—23.45






**3da**, CDCl<sub>3</sub>, 300 MHz



—207.64



**3da**, CDCl<sub>3</sub>, 75 MHz

—59.12


~40.15


—36.22

~32.68


—23.41

—7.86






**3ea**, CDCl<sub>3</sub>, 300 MHz







**3ea**, CDCl<sub>3</sub>, 75 MHz

— 203.49

— 134.39

— 127.50

— 127.45

— 125.72


— 59.35


— 43.89

— 40.39


— 32.53


— 23.56







**3fa**, CDCl<sub>3</sub>, 300 MHz







**3fa**, CDCl<sub>3</sub>, 75 MHz







**3ga**, CDCl<sub>3</sub>, 300 MHz







**3ga**, CDCl<sub>3</sub>, 75 MHz







**5ga**, CDCl<sub>3</sub>, 300 MHz






**5ga**, CDCl<sub>3</sub>, 75 MHz







**3ha**, CDCl<sub>3</sub>, 300 MHz










**3ha**, CDCl<sub>3</sub>, 75 MHz





**3ia**, CDCl<sub>3</sub>, 300 MHz





**3ia**, CDCl<sub>3</sub>, 75 MHz

—194.87

—168.01

—164.61

<131.09

<130.96

<116.27


<115.98


—59.36

—40.67


—29.76


—23.57







**3ja**, CDCl<sub>3</sub>, 300 MHz







**3ja**, CDCl<sub>3</sub>, 75 MHz







**3ka**, CDCl<sub>3</sub>, 300 MHz





**3ka**, CDCl<sub>3</sub>, 75 MHz





**3la**, CDCl<sub>3</sub>, 300 MHz

7.939  
7.915  
7.637  
7.631  
7.611  
7.572  
7.546  
7.523  
7.457  
7.431  
7.407  
7.373  
7.364  
7.344  
7.318  
7.295

5.219  
5.208  
5.189  
5.177

4.196  
4.185  
4.137  
4.125  
3.774  
3.743  
3.714  
3.684

2.05

2.04

0.97

2.07

3.10

1.00

1.01


1.03

9.03


f1 (ppm)


750  
700  
650  
600  
550  
500  
450  
400  
350  
300  
250  
200  
150  
100  
50  
0  
-50







**3a**, CDCl<sub>3</sub>, 75 MHz







**3ma**, CDCl<sub>3</sub>, 300 MHz







**3ma**, CDCl<sub>3</sub>, 75 MHz







**3na**, CDCl<sub>3</sub>, 300 MHz






**3na**, CDCl<sub>3</sub>, 75 MHz






**30a**, CDCl<sub>3</sub>, 300 MHz



—206.65



**30a**, CDCl<sub>3</sub>, 75 MHz

—80.61

—73.86

—59.25

—48.19

—40.02

—39.91

—34.55

—31.64

—30.47

—25.84


—23.52


—23.38

—22.39


—21.09

—16.35







**3pa**, CDCl<sub>3</sub>, 300 MHz










**3pa**, CDCl<sub>3</sub>, 75 MHz







**4ba**, CDCl<sub>3</sub>, 300 MHz







**4ba**, CDCl<sub>3</sub>, 75 MHz







**4bb**, CDCl<sub>3</sub>, 300 MHz







**4bb**, CDCl<sub>3</sub>, 75 MHz







**4bc**, CDCl<sub>3</sub>, 300 MHz






**4bc**, CDCl<sub>3</sub>, 75 MHz






**4ha**, CDCl<sub>3</sub>, 300 MHz









**4ha**, CDCl<sub>3</sub>, 75 MHz


— 141.98  
— 133.76  
— 128.95  
— 127.18


— 71.83  
— 59.33  
— 42.10  
— 30.15  
— 23.59







**4ia**, CDCl<sub>3</sub>, 300 MHz







**4ia**, CDCl<sub>3</sub>, 75 MHz







**4ka**, CDCl<sub>3</sub>, 300 MHz







**4ka**, CDCl<sub>3</sub>, 75 MHz





**4ma**, CDCl<sub>3</sub>, 300 MHz





**4ma**, CDCl<sub>3</sub>, 75 MHz

